NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market Thursday that it has licensed exclusive rights from Johns Hopkins University to patents covering a gene related to pancreatic cancer.

The Salt Lake City-based molecular diagnostics firm said the worldwide, exclusive license covers rights to patents covering mutations in the PALB2 gene, which have been found to increase an individual's risk for developing pancreatic cancer. The company hopes to launch a new predictive test next year containing markers for hereditary pancreatic cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.